Gilead Sciences
Gilead Sciences is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for life-threatening diseases. The company's core value proposition centers on transforming care in therapeutic areas with high unmet medical needs, particularly virology, oncology, and inflammation. Its primary revenue drivers include a robust portfolio of antiretroviral therapies for HIV and advanced treatments for viral hepatitis and cancer.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Virology
primaryThis segment focuses on the treatment and prevention of viral infections, including HIV, viral hepatitis (HBV/HCV/HDV), and COVID-19. It represents the company's historical core and remains the primary driver of total product sales.
Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo, Epclusa, Vemlidy, Veklury
Wholesalers, Hospitals, Physicians, Government health agencies
Oncology
majorThis segment develops and commercializes advanced cancer therapies, including cell therapies and antibody-drug conjugates. It is a major growth area for the company, targeting various lymphomas and breast cancers.
Yescarta, Tecartus, Trodelvy
Specialty distributors, Oncology clinics, Hospitals, Cancer centers
Other Therapeutic Areas
moderateThis segment includes specialized treatments for serious invasive fungal infections and other inflammatory conditions.
AmBisome, Livdelzi
Hospitals, Specialty pharmacies, Healthcare providers
Segment Financials
Reportable Segment — Selling and marketing expenses
View metricReportable Segment — General and administrative expenses
View metricBusiness Overview
Competitive Position
Gilead holds a dominant market position in HIV treatment and is a significant player in the CAR T-cell therapy and oncology markets.
Geographies
United States, Europe, International
Customer Segments
Healthcare providers, Pharmaceutical wholesalers, Government payers, Private insurers
Upstream Dependencies
Contract manufacturing organizations (CMOs), Contract research organizations (CROs), Raw material suppliers, Contract testing laboratories (CTLs)
Downstream Customers
Pharmaceutical wholesalers, Specialty distributors, Hospitals, Retail pharmacies, Government health programs
Competitors & Partners
Similar Companies
Merck & Co.
MRK
AbbVie
ABBV
Johnson & Johnson
JNJ
Alnylam Pharmaceuticals
ALNY
Biogen
BIIB
Regeneron Pharmaceuticals
REGN
Roivant Sciences
ROIV
Agilent Technologies
A
Danaher
DHR
Royalty Pharma
RPRX
Amgen
AMGN
Eli Lilly
LLY
Viatris
VTRS
Pfizer
PFE
Thermo Fisher Scientific
TMO
Natera, Inc.
NTRA
Insmed
INSM
United Therapeutics
UTHR
STERIS
STE
Partners
Merck & Co.
MRK
Collaboration on HIV treatment combinations (islatravir/lenacapavir) and oncology combinations (Trodelvy/pembrolizumab)
Arcus Biosciences
RCUS
Collaboration on oncology candidates domvanalimab and zimberelimab
Johnson & Johnson
JNJ
Collaboration on HIV products Odefsey and Symtuza
Cardinal Health
CAH
Major wholesale distribution partner
Cencora
COR
Major wholesale distribution partner
McKesson
MCK
Major wholesale distribution partner
Subsidiaries
Asegua Therapeutics LLC
Subsidiary for distribution of authorized generic versions of hepatitis C products
Kite Pharma
Cell therapy business unit (implied by Yescarta/Tecartus and manufacturing sites)
Gilead Sciences FAQ
Common questions about Gilead Sciences
Gilead Sciences is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for life-threatening diseases. The company's core value proposition centers on transforming care in therapeutic areas with high unmet medical needs, particularly virology, oncology, and inflammation. Its primary revenue drivers include a robust portfolio of antiretroviral therapies for HIV and advanced treatments for viral hepatitis and cancer.
Gilead Sciences (GILD) has a market capitalization of $162.02B and trades on NASDAQ.
Gilead Sciences generated $29.7B in trailing twelve-month revenue with net income of $9.2B, representing a net margin of 31.0%. Gross margin stands at 79.3%, with free cash flow of $10.2B. These figures are based on the Q1 2026 filing.
Gilead Sciences's key competitors include Bristol-Myers Squibb, Merck & Co., Inc., ABBVIE INC., and others. These companies compete in similar markets and product categories.
Gilead Sciences has approximately 18,000 employees.